Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Br J Dermatol. 2021 May 4;185(2):294–301. doi: 10.1111/bjd.19891

Figure 1. Role of GCNT2 in cancer progression.

Figure 1.

Dysregulated GCNT2 expression in various cancers (A). Metastatic melanoma displays a unique progressive loss of GCNT2 and GCNT2-synthesized I-branched glycans that correlates with disease progression (B). Created with BioRender.com and Reactome64.